An interventional study of Male-specific psychotherapeutic program (MSPP) and Cognitive beahvioral therapy (CBT) in Major Depressive Disorder, sponsored by Andreas Walther. Recruiting at 1 site in Switzerland. Open to male participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Andreas Walther · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 6th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2023, is one of 18 with no phase, and was the 16th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:
University of Bern · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 21+
University of Bern · Sites in Switzerland
Ages 20–75 · Healthy volunteers
Christoph Nissen · Sites in Switzerland
Ages 30–60 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–65
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 25 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 244 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 60 across the 25 interventional studies, 190 across the 5 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Andreas Walther as lead sponsor.
Andreas Walther has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder, Major with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059234University of BernThe Motor Activity - Subjective Energy (MASE) Project | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This project aims to evaluate a male-specific psychotherapeutic program (MSPP) for MDD based on cognitive behavioral therapy (CBT). The primary goal is to test the superiority of the MSPP. This will be conducted in two groups of depressed men, namely eudonadal depressed men and hypogonadal depressed men receiving testosterone treatment (TT). In a randomized study design, the MSPP will be compared to a standard CBT and a waitlist control group, resulting in a total of six study groups. Both standardized psychotherapy programs will encompass 18 sessions delivered in a weekly manner, starting at study week 6 and continuing until study week 24. Aligned with the TT-related medical visits of the hypogonadal men, all participants will be followed up with clinical assessments and biosampling at weeks 0, 6, 15, 24, 36. In addition, a separate healthy control group will be examined, which will undergo only baseline assessments.
Background: Although women are twice as likely to suffer from major depressive disorder (MDD) than men, there are still over 100 million men affected by this condition worldwide. Unfortunately, men suffering from MDD seek mental health services about 30% less than women, leaving a large portion of men with unresolved mental health needs. This is reflected in 2-fold higher rates of alcohol use disorder and 4-fold higher rates of completed suicide amongst men, while MDD is considered a prime risk factor for both. A case is made for male-typical MDD phenotypes with differing symptom presentation often unrecognized by clinicians. Although cognitive behavioral therapy (CBT) represents an effective treatment for MDD, conformity to traditional masculinity norms based on stoicism, self-reliance, and restrictive emotionality often hinder men from engaging in psychotherapy. Therefore, a need to address this diagnostic and treatment gap emerges, while recent studies have identified a lack of male-specific psychotherapeutic programs (MSPP) that could persuade more men to take on psychotherapy based on a male-tailored nature, focusing on male-specific topics and being introduced in male-typical environments.
Method and study procedures: In total, 144 depressed men aged between 25 and 50 will be recruited. After Screening procedures, included participants are stratified by testosterone status (hypogoadal vs. eugonadal) and randomized to one of the conditions: MSPP, CBT, Waitlist. This results in six intervention groups (MSPP, CBT, Waitlist, MSPP+TT, CBT+TT, Waitlist+TT). Hypogonadal men will receive testosterone treatment administered at the Andrology-Urology Center (Uroviva). MSPP and CBT intervention groups will receive weekly therapy sessions for MDD over 18 weeks. All participants will be invited to a total of five examination appointments (weeks 0, 6, 15, 24, 36) at the psychological institute of the university of Zurich. In addition, a separate healthy control group will be examined, which will undergo only baseline assessments.
Expected results: Compared to the waitlist control groups, the treatment groups are expected to be more effective and efficacious (depression score reduction of ≥50%) at week 24 and at follow-up week 36. The MSPP, compared to CBT, is expected to show higher effectiveness and efficacy for depression symptoms, higher acceptability and a greater reduction of gender role conflict. In addition, it is expected that the initially hypogonadal men will have increased symptom improvement due to TT as compared to the eugonadal men in the parallel groups and that TT receiving men show an adjunct effect of added psychotherapy as compared to men in the waitlist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current or previous psychological treatment for any psychological disorder
Any of the following physical conditions, particularly relevant in regard to testosterone treatment:
Current treatment with:
Genetic / hormonal disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this treatment group, eugonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting.
Behavioral: Male-specific psychotherapeutic program (MSPP)
In this treatment group, depressed men will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting.
Behavioral: Cognitive beahvioral therapy (CBT)
The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality.
In this treatment group, hypogonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
Behavioral: Male-specific psychotherapeutic program (MSPP)
In this treatment group, hypogonadal depressed men (blood testosterone ≤ 12.1 nmol/l) will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
Behavioral: Cognitive beahvioral therapy (CBT)
The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.
Change from baseline observer assessed depressive symptomatology to post treatment
Observer assessed depressive symptomatology measured with the Hamilton Depression Rating Scale (HDRS-21)
Time frame: baseline / 24 weeks
Changes in the clinical symptomatology from baseline to post treatment
Observer assessed clinical symptomatology measured with the Clinical Global impression Scale (CGI-S/I)
Time frame: baseline / 24 weeks
Change from baseline male typical depressive symptomatology to post treatment
Self-reported male typical depression symptoms including externalizing behavior such as aggression, risk taking, or alcohol consumption measured with the Male Depression Risk Scale (MDRS-22)
Time frame: baseline / 24 weeks
Change from baseline self-reported depressive symptomatology to post treatment
self-reported depressive symptomatology measured with the Beck Depression Inventory (BDI-II)
Time frame: baseline / 24 weeks
Changes in gender role conflict
Self-reported symptoms of gender role conflict measured with the Gender Role Conflict Scale (GRCS-16)
Time frame: baseline / 24 weeks
Drop out
Acceptability: Proportion of men who withdraw for any reason (dropout) will be recorded and if dropped out participants consent, a dropout interview will be conducted to examine the reasons for dropout.
Time frame: at follow up week 36
Achieved remission
Proportion of participants, that achieved depressive symptom remission (assessed by structured clinical interview \[SCID-5-CV\] for DSM-V disorders)
Time frame: post treatment week 24
Changes in the therapeutic alliance quality
Self reported working alliance quality with the therapist
Time frame: week 6 / week 24
Skala Suizidales Erleben und Verhalten (SSEV-9)
Self-reported suicidal experience and behavior
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Suicide Cognitions Scales (SCS-18)
Self-reported attitudes toward suicide
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Problematic Pornography Consumption Scale (PPCS-18)
Self-reported pornography use and problematic consumption
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Alcohol Use Disorder Test 10 (AUDIT-10)
Self-reported alcohol consumption symptomatology
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
International Index of Erectile Function 15 (IIEF-15)
Self-reported sexual dysfunction and libido symptomatology
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Perceived Stress Scale (PSS-10)
Self-reported subjective stress
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Generalized Anxiety Disorder (GAD-7)
Self-reported general anxiety
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Conformity Masculine Norms Inventory (CMNI-30)
Self-reported conformity to traditional male role norms
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Male Role Norms Inventory - Short Form (MRNI-SF-21)
Self-reported socially learned male role norms
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Precarious Manhood Beliefs Scale (PMB-4)
Self-reported precarious manhood beliefs
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Loneliness Scale (LS-20)
Self-reported feeling of loneliness and social isolation
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Self-Compassion Scale D (SCS-D 10)
Self-reported Positive attitude towards oneself in difficult life situations
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Emotion Regulation Questionnaire (ERQ-10)
Self-reported tendency to re-evaluate / suppress emotions
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
General Belongingness Scale (GBS)
Self-reported achieved belongingness
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
CIDI-Traumaliste (CIDI-T-12)
Assessment of self-reported traumatic experiences over the life span
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
International Trauma Questionnaire (ITQ-18)
Self-reported core symptoms of post-traumatic stress disorder and complex post-traumatic stress disorder
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Agression Questionnaire Buss and Perry (AQ-BP)
Self-reported anger and aggression symptomatology
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Fragebogens zum Körperbild (FKB-6)
Self-reported attitudes towards one's own and an ideal body image
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Male Body Attitudes Scale-Revised (MBAS-R-15)
Self-reported male-specific body (dis)satisfaction
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Body Appreciation Scale 2 (BAS-2-10)
Self-reported assessment of a positive body image
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Stigma questionnaire (STIG-9)
Self-reported experienced stigma for suffering from a mental illness
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Self-stigma of seeking psychological help (SSOSH-10)
Self-reported experienced stigma of seeking help
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
SHAME Questionnaire (SHAME-21)
Self-reported physical, cognitive and existential shame
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Test of Self-Conscious Affect (TOSCA-16)
Assessment of susceptibility to guilt, shame, externalization, and unconcern (self-report questionnaire).
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Toronto Alexithymia Scale (TAS-20)
Self-reported difficulty identifying and describing emotions
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Multidimensional Self-Concept Scale (MSCS)
Self-reported self-concept (self-worth)
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Arnett Inventory of Sensation Seeking (AISS-20)
Self-reported seeking of intense experiences including risky behavior
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Need to Belong Scale (NTBS-10)
Self-reported motivation to be accepted by others and avoidance of rejection by others
Time frame: baseline / week 6 / post treatment week 24 / follow up week 36
Body composition
Body composition is determined by using bioelectrical impedance analysis (BIA)
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Blood testosteron
Blood samples are collected at each study visit to assess blood testosterone
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Hair testosterone
Hair samples are collected at each study visit to assess hair testosterone
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Grip strength
Grip strength will be assessed with a basic hydraulic hand dynamometer at each study visit
Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Oct 2025, 30 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 30 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.